Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Rhea-AI Summary

Sagimet Biosciences to participate in fireside chat and investor meetings at NASH Investor Conference

Positive

• Sagimet Biosciences will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference.
• The company's management will be present at the conference, which could positively impact investor sentiment.
• A webcast of the event will be available on Sagimet's website.

Negative

• None.

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced that management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.

A webcast will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the event.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH), for which there are no treatments currently approved in the United States or Europe. Denifanstat is currently being tested in FASCINATE-2, a Phase 2b clinical trial in NASH with liver biopsy as the primary endpoint. For additional information about Sagimet, please visit www.sagimet.com.

Contact:

Maria Yonkoski
ICR Westwicke
203-682-7167
maria.yonkoski@westwicke.com

FAQ

What is Sagimet Biosciences?

Sagimet Biosciences is a clinical-stage biopharmaceutical company.

What is the H.C. Wainwright 7th Annual NASH Investor Conference?

The H.C. Wainwright 7th Annual NASH Investor Conference is an event focused on Nonalcoholic Steatohepatitis (NASH) investing.

When will the conference take place?

The conference will take place on Tuesday, October 24, 2023.

Where can I watch the webcast of the event?

The webcast will be available on Sagimet's website at www.sagimet.com.